PitchSend

Investor Presentaiton

Investor presentation First three months of 2017 Slide 59 The combined GLP-1 segment accounts for around 4% of the total diabetes care market in Japan & Korea Japan & Korea GLP-1 market VictozaⓇ dulaglutide - other exenatide GLP-1 value in bDKK 1.2 1.0 CAGR value¹: 22.0% 0.8 0.6 0.4 0.2 0.0 Feb 2012 1 CAGR for 5-year period Source: IMS Monthly MAT February, 2017 value figures (DKK) changing diabetes VictozaⓇ value market share in Japan & Korea Share of total diabetes care market 3% GLP-1 value market share VictozaⓇ dulaglutide other exenatide 100% 80% 2% 60% 55% 40% 1% 20% 0% 0% Feb 2017 Feb 2012 Source: IMS Monthly MAT February, 2017 value figures (DKK) 28% 11% 6% Feb 2017 novo nordisk

View entire presentation